343 related articles for article (PubMed ID: 34405554)
1. How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
Csoke E; Landes S; Francis MJ; Ma L; Teotico Pohlhaus D; Anquez-Traxler C
Clin Transl Sci; 2022 Jan; 15(1):43-54. PubMed ID: 34405554
[TBL] [Abstract][Full Text] [Related]
2. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
Clin Pharmacol Ther; 2022 Jan; 111(1):310-320. PubMed ID: 34689334
[TBL] [Abstract][Full Text] [Related]
3. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
[TBL] [Abstract][Full Text] [Related]
4. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM.
Kühler TC; Ateka A; Lassoued Z; Routhier FX; Mékary-Sawaya S
Clin Ther; 2024 Mar; 46(3):208-216. PubMed ID: 38278703
[TBL] [Abstract][Full Text] [Related]
5. [The application of real-world evidence in drug regulatory decision-making].
Wicherski J; Haenisch B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723
[TBL] [Abstract][Full Text] [Related]
6. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
Lee H; Ahn HS; Kwon S; Kang HY; Han E
Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
[TBL] [Abstract][Full Text] [Related]
7. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
[TBL] [Abstract][Full Text] [Related]
8. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019.
Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
J Cancer Policy; 2023 Jun; 36():100424. PubMed ID: 37116794
[TBL] [Abstract][Full Text] [Related]
9. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
F1000Res; 2018; 7():111. PubMed ID: 30026923
[TBL] [Abstract][Full Text] [Related]
10. Translational hurdles with cannabis medicines.
Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
[TBL] [Abstract][Full Text] [Related]
11. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
12. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
13. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
Zisis K; Pavi E; Geitona M; Athanasakis K
J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
[No Abstract] [Full Text] [Related]
14. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Yuan L; Rahman M; Concato J
Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C;
Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555
[TBL] [Abstract][Full Text] [Related]
16. Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact.
Brown JP; Douglas IJ; Hanif S; Thwaites RMA; Bate A
Value Health; 2021 Sep; 24(9):1241-1244. PubMed ID: 34452702
[TBL] [Abstract][Full Text] [Related]
17. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
18. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
19. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making.
Klonoff DC
J Diabetes Sci Technol; 2020 Jan; 14(1):174-179. PubMed ID: 30841738
[TBL] [Abstract][Full Text] [Related]
20. Use of real-world evidence for oncology clinical decision making in emerging economies.
Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]